Subtopic Deep Dive
Epidemiology of Chronic Hepatitis B
Research Guide
What is Epidemiology of Chronic Hepatitis B?
Epidemiology of Chronic Hepatitis B studies the global prevalence, genotypes, transmission patterns, risk factors, and disease burden of persistent HBV infection using serosurveys, cohort studies, and modeling.
Chronic HBV affects 250 million carriers worldwide, with highest prevalence in Asia and Africa. Key studies estimate seroprevalence and model vaccination impacts (Mohd Hanafiah et al., 2012, 2492 citations). Guidelines integrate epidemiological data for management (Lok and McMahon, 2007, 3090 citations; Lampertico et al., 2017, 5284 citations).
Why It Matters
Epidemiological data direct vaccination programs and screening in high-burden regions, reducing hepatocellular carcinoma incidence linked to chronic HBV (Bruix and Sherman, 2005, 5858 citations). Accurate prevalence estimates inform WHO elimination targets by modeling transmission dynamics (Terrault et al., 2018, 4077 citations). Regional guidelines adapt strategies based on genotype distributions and risk factors (Sarin et al., 2015, 2504 citations).
Key Research Challenges
Heterogeneous Global Prevalence
Prevalence varies widely by region, complicating global burden estimates from serosurveys. Modeling must account for underreporting in low-resource areas (Mohd Hanafiah et al., 2012). Standardization of diagnostic criteria remains inconsistent across studies.
Genotype-Transmission Linkage
Linking HBV genotypes to transmission modes and outcomes requires large cohort data. Genotypic diversity affects vaccine efficacy and antiviral response (Lampertico et al., 2017). Surveillance gaps hinder real-time tracking.
Long-term Burden Modeling
Projecting cirrhosis and HCC risks over decades demands robust cohort follow-up. Vaccination impact models integrate incomplete immunization data (Lok and McMahon, 2007). Uncertainty in aging carrier populations challenges predictions.
Essential Papers
Management of Hepatocellular Carcinoma *
Jordi Bruix, Morris Sherman · 2005 · Hepatology · 5.9K citations
CLT, Cadaveric liver transplantation; LDLT, live donor liver transplantation; PEI, Percutanoeus ethanol injection; RF, radiofrequency; TACE, Transarterial chemoembolization; PS, Performance Status....
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Pietro Lampertico, Kosh Agarwal, Thomas Berg et al. · 2017 · Journal of Hepatology · 5.3K citations
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero, Laura Kulik, Claude B. Sirlin et al. · 2018 · Hepatology · 4.4K citations
Marrero, Jorge A.; Kulik, Laura M.; Sirlin, Claude B.; Zhu, Andrew X.; Finn, Richard S.; Abecassis, Michael M.; Roberts, Lewis R.; Heimbach, Julie K. Author Information
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault, Anna S. Lok, Brian J. McMahon et al. · 2018 · Hepatology · 4.1K citations
Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jonas consults for Gile...
Chronic hepatitis B
Anna S. Lok, Brian J. McMahon · 2007 · Hepatology · 3.1K citations
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
Unknown · 2012 · Journal of Hepatology · 2.9K citations
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Shiv Kumar Sarin, Manoj Kumar, George Lau et al. · 2015 · Hepatology International · 2.5K citations
Reading Guide
Foundational Papers
Start with Lok and McMahon (2007, 3090 citations) for core chronic HBV overview, then Bruix and Sherman (2005, 5858 citations) for HCC epidemiology links, followed by Mohd Hanafiah et al. (2012, 2492 citations) for global prevalence methods.
Recent Advances
Study Lampertico et al. (2017, 5284 citations) EASL guidelines and Terrault et al. (2018, 4077 citations) AASLD guidance for updated burden estimates; Sarin et al. (2015, 2504 citations) for Asia-Pacific data.
Core Methods
Serosurveys for HBsAg prevalence; cohort studies for progression risks; mathematical modeling (e.g., GBD2010 approaches) for burden and intervention impacts.
How PapersFlow Helps You Research Epidemiology of Chronic Hepatitis B
Discover & Search
Research Agent uses searchPapers and exaSearch to find epidemiology papers like 'Global epidemiology of hepatitis C virus infection' by Mohd Hanafiah et al. (2012), then citationGraph reveals forward citations in HBV guidelines (Terrault et al., 2018), and findSimilarPapers uncovers regional serosurveys.
Analyze & Verify
Analysis Agent applies readPaperContent to extract prevalence data from Lok and McMahon (2007), verifies burden estimates with runPythonAnalysis on cohort stats using pandas for age-specific seroprevalence, and employs verifyResponse (CoVe) with GRADE grading to assess evidence quality in guidelines (Lampertico et al., 2017).
Synthesize & Write
Synthesis Agent detects gaps in genotype epidemiology coverage across papers, flags contradictions in prevalence models, while Writing Agent uses latexEditText, latexSyncCitations for guideline summaries, and latexCompile to generate formatted reports with exportMermaid for transmission flowcharts.
Use Cases
"Model HBV prevalence decline post-vaccination in Asia using cohort data."
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on seroprevalence from Sarin et al., 2015) → fitted decline curves and visualizations.
"Draft LaTeX review on chronic HBV epidemiology guidelines."
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Lok 2007, Lampertico 2017) → latexCompile → peer-ready PDF with citations.
"Find code for HBV transmission modeling from papers."
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → executable R/Python scripts for serosurvey simulations.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ HBV epidemiology papers, chaining searchPapers → citationGraph → structured prevalence report with GRADE scores. DeepScan applies 7-step analysis to verify burden models from Mohd Hanafiah et al. (2012) with CoVe checkpoints. Theorizer generates hypotheses on genotype impacts from guideline contradictions (Terrault et al., 2018).
Frequently Asked Questions
What defines chronic Hepatitis B epidemiology?
It tracks HBV prevalence, genotypes, transmission, and burden via serosurveys and cohorts, estimating 250 million carriers globally.
What methods track HBV prevalence?
Serosurveys measure HBsAg, cohorts follow outcomes, and modeling estimates vaccination effects (Mohd Hanafiah et al., 2012; Lok and McMahon, 2007).
What are key papers?
Lok and McMahon (2007, 3090 citations) on chronic HBV; Lampertico et al. (2017, 5284 citations) EASL guidelines; Terrault et al. (2018, 4077 citations) AASLD update.
What open problems exist?
Gaps include real-time genotype surveillance, aging carrier projections, and standardized modeling across regions with heterogeneous data.
Research Hepatitis B Virus Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Epidemiology of Chronic Hepatitis B with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hepatitis B Virus Studies Research Guide